Related Tags >> Eli Lilly Daiichi Sankyo FDA FDA approval

prasugrel News

Most Popular prasugrel Story

Lilly submits prasugrel NDA

January 4, 2008 — 7:59am ET

Eli Lilly and Daiichi Sankyo have submitted the much-watched drug prasugrel to the FDA. The drug--an oral antiplatelet agent--is poised to take on the blockbuster Plavix. Read more...

prasugrel Press Releases

FDA Continues to Review Prasugrel New Drug Application
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
Daiichi Sankyo, Lilly Submit NDA for Investigational Antiplatelet Drug, Prasugrel, to FDA
PRESS RELEASE: In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel

Latest Headlines

Daiichi, Lilly: still no word on prasugrel
October 17, 2008
FDA again delays prasugrel decision
September 29, 2008
Deadline clock running on Lilly's next big blockbuster
September 22, 2008
Biopharma sees tougher FDA approval process
June 30, 2008
FDA delays review of Eli Lilly’s would-be blockbuster
June 24, 2008
Prasugrel gets priority review
February 22, 2008
Lilly submits prasugrel NDA
January 4, 2008
Lilly drug outperforms Plavix, but there's a catch
November 5, 2007
Lilly suspends dosing in crucial drug trial
October 25, 2007

Paid Research Reports